BeiGene
BGNE
#966
Rank
C$29.30 B
Marketcap
$267.86
Share price
0.49%
Change (1 day)
17.74%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$22.50

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$24.13. In 2022 the company made an earnings per share (EPS) of -$28.09 a decrease over its 2021 EPS that were of -$22.06.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$22.50-19.89%
2022-$28.0927.35%
2021-$22.06-19.96%
2020-$27.5620.81%
2019-$22.8131.52%
2018-$17.34417.57%
2017-$3.35-37.16%
2016-$5.33158.95%
2015-$2.06

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.45-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.39-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA